Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 9841 | Ordered by Date (descending)
1 2 3 ... 97 98 99  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
ArgusEye–Eir Ventures: investment, 202405 financing round totalling €2.8m incl existing + co-lead investor Eir Ventures 2024-05-13
ArgusEye–SEVERAL: investment, 202405 financing round €2.8m led by Voima Ventures + co-led by Eir Ventures 2024-05-13
ArgusEye–Voima Ventures: investment, 202405 financing round totalling €2.8m incl lead investor Voima Ventures 2024-05-13
BioVersys–GSK: investment, 202403 financing round Series C extension totalling CHF12.3m incl investor GSK as part of collab 2024-05-07
BioVersys–SEVERAL: investment, 202403 financing round Series C extension CHF12.3m bringing total Series C to CHF44.9m 2024-05-07
GSK–BioVersys: alpibectir, 202405– collab expansion to speed up development to treat tuberculosis 2024-05-07
Insempra–Acequia Capital: investment, 202405 financing round Series A totalling $20m incl existing investor Acequia Capital 2024-05-07
Insempra–Alante Capital: investment, 202405 financing round Series A totalling $20m incl new investor Alante Capital 2024-05-07
Insempra–Bavaria (govt): investment, 202405 financing round Series A totalling $20m incl new investor Bayern Kapital 2024-05-07
Insempra–BY Capital: investment, 202405 financing round Series A totalling $20m incl existing investor BlueYard Capital 2024-05-07
Insempra–EQT: investment, 202405 financing round Series A totalling $20m incl existing investor EQT Ventures 2024-05-07
Insempra–Henkel: investment, 202405 financing round Series A totalling $20m incl new investor Henkel dx Ventures 2024-05-07
Insempra–Possible Ventures: investment, 202405 financing round Series A totalling $20m incl existing investor Possible Ventures 2024-05-07
Insempra–SEVERAL: investment, 202405 financing round Series A $20m with existing + new investors 2024-05-07
Insempra–Taavet+Sten: investment, 202405 financing round Series A totalling $20m incl existing investor Taavet Sten 2024-05-07
Memo Therapeutics–Adjuvant Capital: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Adjuvant Capital 2024-05-07
Memo Therapeutics–Bellevue: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Pureos Bioventures 2024-05-07
Memo Therapeutics–Eurazeo: investment, 202405 financing round Series C extension totalling CHF20m incl new investor Kurma Partners 2024-05-07
Memo Therapeutics–Fresenius: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor FMCV 2024-05-07
Memo Therapeutics–GF Group: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor GF Group 2024-05-07
Memo Therapeutics–ICR: public relations, 202405 service existent ICR Consilium is media contact 2024-05-07
Memo Therapeutics–Redalpine: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Red Alpine 2024-05-07
Memo Therapeutics–Schroders: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Schroders Capital 2024-05-07
Memo Therapeutics–SEVERAL: investment, 202405 financing round Series C extension CHF20m bringing total Series C to CHF45m 2024-05-07
Memo Therapeutics–Verve Capital Partners: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Verve Ventures 2024-05-07
Memo Therapeutics–Vesalius Biocapital: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Vesalius 2024-05-07
Memo Therapeutics–Ysios Capital: investment, 202405 financing round Series C extension totalling CHF20m incl new investor Ysios Capital 2024-05-07
Memo Therapeutics–Zürcher Kantonalbank: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Swisscanto 2024-05-07
Mariana Oncology–Novartis: investment, 202405– acquisition $1b upfront + $750m milestones of Mariana Oncology by Novartis 2024-05-02
Bayer–Evotec: drug discovery services, 202404– update to strategic collab €na with new focus on precision cardiology usinsg iPSCs 2024-04-30
Novartis–PeptiDream: drug discovery, 202404– collab expansion $180m upfront + $2.71b milesotnes discovery peptides for conjugation to radionuclides 2024-04-30
Locate Bio–BGF (GB): investment, 202404 financing round totalling £9.2m incl investor BGF 2024-04-29
Locate Bio–Mercia: investment, 202404 financing round totalling £9.2m incl investor Mercia Ventures 2024-04-29
Locate Bio–SEVERAL: investment, 202404 financing round £9.2m with Mercia Ventures + BGF 2024-04-29
Variantyx–Bosch: investment, 202404 financing round totalling $36m incl existing investor Bosch Ventures 2024-04-26
Variantyx–New Era Capital: investment, 202404 financing round totalling $36m incl existing investor New Era Capital Partners 2024-04-26
Variantyx–Peregrine Ventures: investment, 202404 financing round totalling $36m incl existing investor Peregrine Ventures 2024-04-26
Variantyx–Pitango: investment, 202404 financing round totalling $36m incl existing investor Pitango HealthTech 2024-04-26
Variantyx–SEVERAL: investment, 202404 financing round $36m from existing investors 2024-04-26
Deepull Diagnostics–ICR: public relations, 202404 service existent ICR Consilium is media contact 2024-04-25
Cultimate Foods–b.value: investment, 202404 seed financing round totalling €2.3m incl co-investor b.value AG 2024-04-23
Cultimate Foods–Big Idea Ventures: investment, 202404 seed financing round totalling €2.3m incl co-investor Big Idea Ventures 2024-04-23
Cultimate Foods–High-Tech Gründerfonds: investment, 202404 seed financing round totalling €2.3m incl lead investor HTGF 2024-04-23
Cultimate Foods–Kale United: investment, 202404 seed financing round totalling €2.3m incl co-investor Kale United 2024-04-23
Cultimate Foods–Life Science Valley: investment, 202404 seed financing round totalling €2.3m incl co-investor LSV Wachstumsfonds 2024-04-23
Cultimate Foods–SEVERAL: investment, 202404 seed financing round €2.3m led by HTGF 2024-04-23
Smart Reporting–SEVERAL: investment, 202404 financing round Series C €23m led by new investor TVM Capital Life Science 2024-04-22
NanoString–Bruker: investment, 202404– acquisition $392.6m of substantially all assets winning bid under Bankruptcy Code 2024-04-17
Theolytics–Epidarex Capital: investment, 202404 financing round totalling £19m incl existing investor Epidarex Capital 2024-04-17
Theolytics–Merck (DE): investment, 202404 financing round totalling £19m incl existing investor M Ventures 2024-04-17
Theolytics–Otsuka: investment, 202404 financing round totalling £19m incl existing investor Taiho Ventures 2024-04-17
Theolytics–Oxford Science Enterprises: investment, 202404 financing round totalling £19m incl existing investor Oxford Science Enterprises 2024-04-17
Theolytics–SEVERAL: investment, 202404 financing round £19m incl new investor Sound Bioventures 2024-04-17
Theolytics–Sound Bioventures: investment, 202404 financing round totalling £19m incl new investor Sound Bioventures 2024-04-17
Theolytics–Univ Oxford: investment, 202404 financing round totalling £19m incl existing investor Univ Oxford 2024-04-17
DeepCure–IAG Capital Partners: investment, 202404 financing round Series A-1 totalling $24m incl lead investor IAG 2024-04-11
DeepCure–SEVERAL: investment, 202404 financing round Series A-1 $24m led by IAG Capital Partners 2024-04-11
FundaMental Pharma–ICR: public relations, 202404 service existent ICR Consilium is media contact 2024-04-11
FundaMental Pharma–Novartis: investment, 202404 investment €2.7m??? by new investor NVF brings total seed financing to €12.7m 2024-04-11
LGC–Asahi Kasei: oligo manufacturing, 202404– collab strategic Axolabs building cGMP oligo manufacturing facility in Berlin using equipment from AKB 2024-04-11
Prothea Technologies–Earlybird: investment, 202404 financing round Series A totalling €12m incl co-lead investor Earlybird Venture Capital 2024-04-09
Prothea Technologies–Mérieux: investment, 202404 financing round Series A totalling €12m incl co-lead investor Mérieux Equity Partners 2024-04-09
Prothea Technologies–North Rhine-Westphalia (govt): investment, 202404 financing round Series A totalling €12m incl co-investor NRW.BANK 2024-04-09
Prothea Technologies–SEVERAL: investment, 202404 financing round Series A €12m co-led by Earlybird + Mérieux Equity Partners 2024-04-09
Prothea Technologies–Univ Edinburgh: investment, 202404 financing round Series A totalling €12m incl co-investor Old College Capital 2024-04-09
Seaport Therapeutics–PureTech Health: investment, 202404 financing round Series A totalling $100m incl founder + co-investor PureTech Health 2024-04-09
Seaport Therapeutics–Ten Bridge Communications: public relations, 202404 service existent Ten Bridge is media contact 2024-04-09
Merck (DE)–Caris Life Sciences: AI-based drug discovery, 202404– collab strategic up to $1.4b discovery of cancer targets for ADC RnD 2024-04-04
Alterome Therapeutics–SEVERAL: investment, 202404 financing round Series B $132m led by Goldman Sachs Alternatives 2024-04-03
ProfoundBio–Genmab: investment, 202403– acqusition $1.8b in cash of ProfoundBio by Genmab ANNOUNCED 2024-04-03
AbnomX–BioLizard: bioinformatics, 202404– collab strategic partnership with regard to complementary offerings 2024-04-02
SurgeCare–50 Partners Santé: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor 50 Partners Santé 2024-03-27
SurgeCare–Boutique Venture: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor Boutique Venture 2024-03-27
SurgeCare–Eurazeo: investment, 202403 2nd financing round totalling €7.5m incl lead investor Eurazeo 2024-03-27
SurgeCare–France (govt): grant, 202403c BPI grants incl support for deep tech development + Future Investment Program 2024-03-27
SurgeCare–HCVC: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor HCVC 2024-03-27
SurgeCare–Kima: investment, 202403 2nd financing round totalling €7.5m incl co-investor Kima 2024-03-27
SurgeCare–MH Innov’: investment, 202403 2nd financing round totalling €7.5m incl co-investor MH Innov’ 2024-03-27
SurgeCare–SEVERAL: investment, 202403 2nd financing round €7.5m led by Eurazeo 2024-03-27
SurgeCare–Teampact Ventures: investment, 202403 2nd financing round totalling €7.5m incl co-investor Teampact 2024-03-27
Innocent Meat–Mecklenburg-Vorpommern (govt): investment, 202403 financing round totalling €3m incl €500k from existing investor VC Fonds MV 2024-03-26
Innocent Meat–OTHER: investment, 202403 financing round totalling €3m incl €2.5m from a new private investor 2024-03-26
Innocent Meat–SEVERAL: investment, 202403 financing round €3m with Venture Capital Fonds MV + new private investor 2024-03-26
Protembis–SEVERAL: investment, –202403 financing round Series B €30m completed in two separate capital increases 2024-03-26
A2 Biotherapeutics–Sam Brown: public relations, 202403 service existent by Sam Brown Inc 2024-03-25
Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED 2024-03-25
Hemotune–SEVERAL: investment, 202403 financing round Series B2 CHF14m led by Belmondo 2024-03-25
Kranus Health–Anaxago: investment, 202403 financing round Series A expansion totalling $5m incl new investor CapHorn 2024-03-25
Kranus Health–Future Positive Capital: investment, 202403 financing round Series A expansion totalling $5m incl new investor Future Positive Capital 2024-03-25
Kranus Health–SEVERAL: investment, 202403 financing round Series A expansion $5m bringing total Series A to $20m 2024-03-25
Volumina Medical–SEVERAL: investment, 202403 financing round Series A $21m with existing + new investors 2024-03-25
Avation Medical–Angelini: investment, 202403 existent investment of Angelini Ventures 2024-03-21
Cadence Neuroscience–Angelini: investment, 202403 existent investment of Angelini Ventures 2024-03-21
Cour Pharmaceuticals–Angelini: investment, 202403 existent investment of Angelini Ventures 2024-03-21
Mirador Therapeutics–Sanofi: investment, 202403 Mirador emerges with total of >$400m in financing incl investor Sanofi Ventures 2024-03-21
Mirador Therapeutics–SEVERAL: investment, 202403 emerges with >$400m in financing led by ARCH Venture with early investments by OrbiMed + Fairmount 2024-03-21
Noctrix Health–Angelini: investment, 202403 existent investment of Angelini Ventures 2024-03-21
Nouscom–Angelini: investment, 202403 investment €7m from Angelini Ventures as Series C extension bringing total round to €75.8m 2024-03-21
Sanofi–Owkin: AI-based drug development, 202403– collab expansion into using AI for drug positioning in immunology 2024-03-21
Capstan Therapeutics–Bayer: investment, 202403 financing round Series B totalling $175m incl existing + co-investor Leaps by Bayer 2024-03-20
1 2 3 ... 97 98 99  next pagenext page



Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px

» top